Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Noboru NakaigawaYoshihiko TomitaSatoshi TamadaKatsunori TatsugamiTakahiro OsawaMototsugu OyaHiroomi KanayamaYuji MiuraNaoto SassaKazuo NishimuraMasahiro NozawaNaoya MasumoriYasuhide MiyoshiShingo KurodaAkiko KimuraPublished in: International journal of clinical oncology (2023)
Updated analyses demonstrate the long-term efficacy and safety of cabozantinib in Japanese patients with advanced RCC after at least one VEGFR-TKI therapy. Responders tended to show lower baseline HGF levels ClinicalTrials.gov Identifier: NCT03339219.
Keyphrases
- renal cell carcinoma
- metastatic renal cell carcinoma
- open label
- tyrosine kinase
- advanced non small cell lung cancer
- clinical trial
- vascular endothelial growth factor
- stem cells
- randomized controlled trial
- double blind
- endothelial cells
- chronic myeloid leukemia
- bone marrow
- study protocol
- epidermal growth factor receptor
- smoking cessation